Biological E. Limited has several firsts
to its credit. It was the first private
sector biological products company in India;
the first pharmaceutical company to manufacture
anti-TB drugs in India and the first private
sector vaccine manufacturer in the country. However, Biological E Limited's standing and reputation lie not in merely being first but in its
long standing and firm commitment to maintaining
the highest quality standards through
constant innovation, partnerships with reputed
institutes and modernization of its manufacturing
facilities.
Biological E Limited is investing approximately US $ 50 Million
towards the development and expansion of
infrastructure. State-of-the-art equipment
is being installed in all locations that
will meet the US FDA and European MEA standards
in manufacturing, quality control and pre-clinical
activities. As per the regulatory requirements
we have
specialized
suites for different manufacturing
activities. Dedicated laboratories have
also been provided to carry out testing
of the quality control setup.
Several projects are underway to strengthen
and expand Biological E Limited's drive to internationalize
its business. One of these is the compact
and well-maintained production facility
to manufacture APIs in Pattancheru, which
has ample scope for future expansion.
Another project underway is the modern Biotech
facility, with an investment of Rs. 100
crores, in the Genome Valley, Andhra Pradesh.
We have taken up this state-of-the-art Technology
project to produce a new generation of vaccines,
focused on reaching out to international
markets. This project complies strictly
with the WHO and US FDA Good Manufacturing
Practices guidelines. |
